具有细胞活动的KMT9抑制剂原药的结构导向设计
Sheng Wang1, Nicolas P F Barthes2, Sylvia Urban1
1Klinik für Urologie und Zentrale Klinische Forschung, Klinikum der Albert-Ludwigs-Universität Freiburg, Freiburg 79106, Germany.
Journal of medicinal chemistry
|June 17, 2025
概括
研究人员开发了强大的KMT9抑制剂用于癌症治疗. 一种前药物形式有效地抑制了结肠癌细胞的增殖,验证了KMT9作为治疗点.
科学领域:
- 生物化学 生物化学
- 分子生物学分子生物学
- 药用化学 医学化学
背景情况:
- 氨酸甲基转移酶9 (KMT9) 是一种基因组甲基转移酶,在氨酸12 (H4K12me1) 中单甲基化基因组H4.
- 抑制KMT9会影响各种癌细胞的增殖,包括前列腺癌,肺癌,结肠癌和膀癌,表明其治疗潜力.
研究的目的:
- 开发KMT9.9的强效和选择性抑制剂.
- 验证KMT9作为癌症治疗的可用药物标.
主要方法:
- 具有甲因侧链的分支辅因子类型的结构导向设计.
- 合成和表征KMT9抑制剂.
- 抑制剂强度和选择性的评估.
- 在结肠癌细胞系中评估前药疗效.
主要成果:
- 与甲氨酸侧链的分支辅因子类似物被确定为高度有效的KMT9抑制剂.
- 特殊的结构特征,包括一个基本的和4-基-2-基,增强的抑制剂功效和选择性.
- 一种乙烯原药 (化合物8) 证明了细胞向的参与.
- 这种前药有效地阻止了结肠癌细胞系的扩散.
结论:
- 药理上抑制KMT9是一种有前途的癌症治疗策略.
- 开发的前药证明了向KMT9用于癌症治疗的潜力.
更多相关视频
10:33Development of Inhibitors of Protein-protein Interactions through REPLACE: Application to the Design and Development Non-ATP Competitive CDK Inhibitors
Published on: October 26, 2015
11.4K
11:17Direct Measurement of KDM1A Target Engagement Using Chemoprobe-based Immunoassays
Published on: June 13, 2019
7.4K
相关概念视频
Structure-Activity Relationships and Drug Design
1.1K
Drug design is a dynamic field that involves discovering and developing new medications based on specific biological targets. This process heavily relies on structure-activity relationships (SAR) and quantitative structure-activity relationships (QSAR) to guide the design and optimization of efficient drugs.
SAR studies the intricate relationship between a drug's chemical structure and biological activity. It focuses on understanding how modifications to a drug's structure can influence...
SAR studies the intricate relationship between a drug's chemical structure and biological activity. It focuses on understanding how modifications to a drug's structure can influence...
1.1K
Targets for Drug Action: Overview
7.5K
Drugs target macromolecules to modify ongoing cellular processes. Primary drug targets include receptors, ion channels, transporters, and enzymes.
Receptors are either membrane-spanning or intracellular proteins, which upon binding a ligand, get activated and transmit the signal downstream to elicit a response. Drugs bind receptors, either mimicking the action of endogenous ligands or blocking the receptor activity to bring about a modified response. Nearly 35% of approved drugs target the G...
Receptors are either membrane-spanning or intracellular proteins, which upon binding a ligand, get activated and transmit the signal downstream to elicit a response. Drugs bind receptors, either mimicking the action of endogenous ligands or blocking the receptor activity to bring about a modified response. Nearly 35% of approved drugs target the G...
7.5K
